blenrep gsk fda - Search News

Order byBest matchMost fresh

News

GSK Shares Drop

· 10h · on MSN

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.

Continue reading

· 15h · on MSN

GSK shares fall after blood cancer drug likely headed for U.S. rejection

GSK’s Blenrep faces setback as FDA cancer committee votes against approval

GSK’s Blenrep Loses Adcomm Vote, Further Clouding Comeback Bid

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

‘Surprising’ setback: ODAC rebuffs Blenrep for multiple myeloma, citing ocular toxicity

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Fierce Pharma3d

As GSK eyes Blenrep's US return, FDA flags eye safety concerns ahead of advisory committee meeting

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results